Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome

Anna J. Moyer, Fabian‐Xosé Fernandez, Yicong Li, Donna Klinedinst, Liliana Florea, Yasuhiro Kazuki, Mitsuo Oshimura, Roger H. Reeves

TL;DR

This study screened human chromosome 21 genes for their ability to modulate the Sonic hedgehog (SHH) signaling pathway, a pathway implicated in many Down syndrome phenotypes. By overexpressing these genes in various cell models, researchers identified several genes that either enhance or inhibit SHH signaling, with four specific genes (B3GALT5, ETS2, HMGN1, and MIS18A) found to inhibit the proliferation of crucial cerebellar cells. These findings pinpoint key genetic players that could contribute to Down syndrome-related developmental issues and suggest potential therapeutic targets.

What Problem Does This Paper Address?

Down syndrome (DS), caused by trisomy of chromosome 21, is associated with a wide range of developmental abnormalities, including cerebellar hypoplasia, craniofacial defects, and heart conditions. The Sonic hedgehog (SHH) signaling pathway is known to be critical for normal development and is implicated in many of these same phenotypes. Interestingly, cells from individuals with DS show dysregulation of SHH signaling. However, chromosome 21 itself doesn't contain any of the core components of the canonical SHH pathway. This raises a crucial question: how do the extra genes on chromosome 21, when present in three copies instead of two, disrupt SHH signaling and contribute to DS phenotypes? This paper aims to identify specific chromosome 21 genes that, when overexpressed, can modulate SHH signaling, thereby providing insights into the genetic basis of DS-related developmental issues.

Methods

The researchers employed a multi-pronged screening approach:

  • High-throughput luciferase reporter assays: They used two SHH-responsive mouse cell lines (Shh-LIGHT2 and SmoA1-LIGHT) engineered to express a luciferase reporter gene under the control of an SHH-responsive promoter. Overexpression of 163 human chromosome 21 cDNAs was tested in these cells, and changes in luciferase activity indicated modulation of SHH signaling.
  • Functional cell-based assay: They used mouse C3H10T1/2 mesenchymal stem cells, which differentiate into osteoblasts in an SHH-dependent manner. Overexpression of chromosome 21 cDNAs was assessed for its effect on alkaline phosphatase activity, an early marker of osteoblast differentiation.
  • RNA sequencing (RNA-seq): They analyzed the gene expression profiles of cerebella from mouse models of DS (Ts65Dn and TcMAC21) to identify which chromosome 21 genes are actually overexpressed in the relevant tissue.
  • Primary granule cell precursor proliferation assay: To assess the impact on a key cell type involved in cerebellar development, they overexpressed candidate genes in primary cerebellar granule cell precursors and measured their proliferation using EdU incorporation.

Datasets

  • Human chromosome 21 cDNA library: A library of 163 human chromosome 21 cDNAs was used for overexpression screens.
  • Mouse models of Down syndrome: Ts65Dn and TcMAC21 mice were used for RNA-seq analysis of cerebellar tissue.
  • BrainSpan Atlas of the Developing Human Brain: Used to assess the expression of candidate genes in human cerebellar samples.
  • Single-cell RNA-seq data from euploid mouse granule cell precursors: Used for comparison of gene expression.

Key Insights and Ideas

  • Dosage matters: The study strongly suggests that the dosage of specific chromosome 21 genes, not just their presence, is critical for disrupting SHH signaling and contributing to DS phenotypes.
  • Indirect modulation: Many of the identified genes are not direct components of the SHH pathway but likely modulate it indirectly through effects on cell cycle regulation, chromatin structure, or other cellular processes.
  • Cerebellar focus: The research specifically targets cerebellar hypoplasia, a common DS phenotype, by examining gene expression and functional effects in cerebellar cells and tissues.
  • Prioritizing candidates: The multi-stage screening approach effectively narrowed down a large set of genes to a few key candidates with consistent effects across different assays.

Key Results

  • Primary screen identified modulators: Overexpression of 163 chromosome 21 cDNAs in SHH-responsive cell lines identified several genes that either activated or inhibited SHH signaling. For instance, DYRK1A was found to upregulate SHH signaling, while HMGN1 inhibited it.
  • Functional validation in osteoblasts: In a functional assay of osteoblast differentiation, six chromosome 21 cDNAs significantly reduced differentiation, indicating SHH pathway attenuation.
  • Cerebellar expression confirmed: RNA-seq analysis of mouse DS models confirmed the overexpression of many chromosome 21 genes in the developing cerebellum.
  • Inhibition of granule cell proliferation: Crucially, overexpression of four genes (B3GALT5, ETS2, HMGN1, and MIS18A) significantly inhibited the proliferation of primary cerebellar granule cell precursors, a key finding linking these genes to a critical developmental process affected in DS.

Limitations and Future Work

  • In vitro vs. in vivo: The study acknowledges that cell culture models cannot fully replicate the complex in vivo environment of trisomy 21, especially regarding genetic interactions and compensatory effects.
  • Supraphysiological overexpression: Transient transfection can lead to supraphysiological levels of gene expression, which might not perfectly reflect the actual gene dosage in trisomic cells.
  • Individual gene effects: The screens focused on the effects of individual gene overexpression, not the combined effects of over 500 genes on chromosome 21, nor potential interactions between them.
  • Future directions: The authors suggest further investigation into the precise molecular mechanisms by which these identified genes modulate SHH signaling. They also emphasize the need for in vivo validation of these candidate genes and the potential for developing therapeutic strategies targeting these pathways to ameliorate DS phenotypes. The complexity of DS phenotypes suggests that a polygenic or oligogenic explanation is more likely than a single gene effect.

Summary updated

Abstract

Trisomy 21 and mutations in the Sonic hedgehog (SHH) signaling pathway cause overlapping and pleiotropic phenotypes including cerebellar hypoplasia, craniofacial abnormalities, congenital heart defects and Hirschsprung disease. Trisomic cells derived from individuals with Down syndrome possess deficits in SHH signaling, suggesting that overexpression of human chromosome 21 genes may contribute to SHH-associated phenotypes by disrupting normal SHH signaling during development. However, chromosome 21 does not encode any known components of the canonical SHH pathway. Here, we sought to identify chromosome 21 genes that modulate SHH signaling by overexpressing 163 chromosome 21 cDNAs in a series of SHH-responsive mouse cell lines. We confirmed overexpression of trisomic candidate genes using RNA sequencing in the cerebella of Ts65Dn and TcMAC21 mice, model systems for Down syndrome. Our findings indicate that some human chromosome 21 genes, including DYRK1A, upregulate SHH signaling, whereas others, such as HMGN1, inhibit SHH signaling. Individual overexpression of four genes (B3GALT5, ETS2, HMGN1 and MIS18A) inhibits the SHH-dependent proliferation of primary granule cell precursors. Our study prioritizes dosage-sensitive chromosome 21 genes for future mechanistic studies. Identification of the genes that modulate SHH signaling may suggest new therapeutic avenues for ameliorating Down syndrome phenotypes.
BibTeX
@inproceedings{moyer2023overexpression,
  author = {Anna J. Moyer and Fabian‐Xosé Fernandez and Yicong Li and Donna Klinedinst and Liliana Florea and Yasuhiro Kazuki and Mitsuo Oshimura and Roger H. Reeves},
  title = {{Overexpression screen of chromosome 21 genes reveals modulators of Sonic hedgehog signaling relevant to Down syndrome}},
  booktitle = {Disease},
  year = {2023},
  doi = {10.1242/dmm.049712},
}
Figure